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Context: Offspring exposed in-utero to maternal obesity have an increased risk of later obesity; 
however, the underlying mechanisms remain unknown.  
Objective: To assess the effect of an antenatal lifestyle intervention in obese women on the 
offspring’s cord blood metabolic profile, and examine associations of cord blood metabolic 
profile with maternal clinical characteristics and offspring anthropometry at birth and age 6 
months.  
Design: Randomised controlled trial and cohort study. 
Setting: The UK Pregnancies Better Eating and Activity randomised controlled trial (UPBEAT). 
Participants: 344 mother-offspring pairs. 
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Intervention: Antenatal behavioural lifestyle (diet and physical activity) intervention. 
Main outcome measures: Targeted cord blood metabolic profile, including candidate hormone 
and metabolomic analyses. 
Results: The lifestyle intervention was not associated with change in the cord blood metabolic 
profile. Higher maternal glycaemia, specifically fasting glucose at 28 weeks’ gestation had a 
linear association with higher cord blood concentrations of lysophosphatidylcholines 16.1 
(β=0.65; 95%CI 0.03 to 0.10) and 18.1 (0.52; 0.02 to 0.80), independent of the lifestyle 
intervention. A principal component of cord blood phosphatidylcholines and 
lysophosphatidylcholines was associated with infant z-scores of birthweight (0.04; 0.02 to 0.07) 
and weight at age 6 months (0.05; 0.00 to 0.10). Cord blood IGF-1 and adiponectin 
concentrations were positively associated with infant weight z-scores at birth and at 6 months.  
 Conclusions: Concentrations of lysophosphatidylcholines and IGF-1 in cord blood are related to 
infant weight. These findings support the hypothesis that susceptibility to childhood obesity may 
be programmed in-utero, but further investigation is required to establish whether these 
associations are causally related.  
Investigation of the cord blood metabolic profile was undertaken in offspring born to obese women 
identifying a novel role of lipid sub-species as a potential determinant of early infancy weight. (Patel N et 
al) 
Introduction 
The increasing incidence of childhood obesity is a major public health concern. Recent global 
estimates from the WHO, suggest that 41 million children under the age of 5 years are 
overweight or obese (1). Observational cohort studies and experimental animal studies have 
strongly suggested that both the pre- and postnatal environments modulate developmental 
pathways that increase susceptibility to later obesity (2). Offspring exposed to maternal obesity, 
excessive gestational weight gain (GWG) and/or gestational diabetes (GDM) in-utero are at an 
increased risk of obesity and altered glucose metabolism throughout the life-course (2, 3). 
Exposure to maternal obesity in-utero is proposed to set offspring on a trajectory of increased 
adiposity throughout life due to persistent changes in metabolic function (4).  
Metabolomics enables the investigation of low-molecular weight molecules such as 
intermediate metabolites and signalling molecules and can be used as a tool to provide insight in 
the systemic perturbations of an individual as a result of pathophysiological in-utero exposure 
(5). Investigations of cord blood metabolic profiles have previously been conducted within small 
cases-control studies assessing associations with birth weight or post-natal trajectories and with 
limited adjustment for in-utero confounding variables. In a large birth cohort from Germany, 
certain cord blood metabolites were associated with birth weight (6). However, neonatal 
adiposity explains only 40% of the observed variation in birthweight.  
To date, no investigations have addressed the relations between maternal clinical and 
biochemical characteristics in obese women and fetal metabolism, in association with neonatal 
and early infancy weight and anthropometric measures of adiposity. We examined these relations 
in a group of obese pregnant women and their offspring who had taken part in the UK 
Pregnancies Better Eating and Activity Trial (UPBEAT); a randomised controlled trial assessing 
a behavioural lifestyle intervention in 1555 obese pregnant women (7). Although the trial 
intervention did not reduce the incidence of GDM and delivery of a large for gestational age 
infant (primary outcomes), we have recently reported a reduction in infant subscapular skinfold 
  3
thickness at 6 months of age mediated through significant improvements in maternal antenatal 
diet, measures of adiposity and GWG initiated by the UPBEAT intervention (8).  
Our primary aim was to determine if the intervention resulted in changes in a targeted cord 
blood metabolic profile and candidate hormones previously implicated with obesity and fetal 
growth. The secondary aim was to explore the relations between maternal antenatal 
characteristics including total GWG, pre-pregnancy BMI and GDM and cord blood metabolic 
profile. As weight and adiposity have been shown to track through childhood, further assessment 
was made for potential relations between metabolites in the cord blood and measures of weight 
and anthropometry in offspring at birth and at 6 months of age. 
Subjects and Methods  
Study Design  
This study was a secondary analysis from the UPBEAT trial (7). To assess the primary aim of 
this study; the influence of the UPBEAT lifestyle intervention on the cord blood metabolic 
profile, the UPBEAT study was treated as an RCT (7). As the secondary aim of the study was to 
assess the relationship of the cord blood metabolic profile with maternal clinical characteristics 
and neonatal and infant anthropometry, an analysis based on a cohort study approach was chosen 
using both active treatment and control groups, and taking into account the original 
randomisation allocation.  
Study population  
Primary aim  
Women over the age of 16 years were recruited to the UPBEAT trial between 15+0-18+6 weeks’ 
gestation. The participants were from inner-city populations with high socioeconomic 
deprivation. The detailed study design including inclusion and exclusion has been previously 
published (7).  
In summary, the UPBEAT study recruited 1555 obese women from 8 tertiary maternity units 
located within inner city populations at 15+0-18+6 weeks’ gestation. A behavioural intervention 
was devised based on psychological models of health behaviour including control and social 
cognitive theory, delivered via weekly sessions to increase physical activity and reduce maternal 
glycaemic load and saturated fat intake. The primary maternal outcome was a reduction in the 
incidence of GDM at 27-28+6 weeks gestation and the neonatal outcome was a reduction in the 
delivery of a large for gestational age infant. Women were randomised using an online database 
with minimisation for ethnicity, parity and BMI, to ensure that the groups were comparable at 
baseline. 47.3% of offspring were followed up at 6 months postpartum. In comparison to those 
who did not take part, the mothers in the follow up study were older, more likely to be White, 
nulliparous and less likely to be current smokers (See Supplement, Table 2). There was no 
significant difference in sessions covered between those who did and did not take part in the 
present study (p=0.09). 
Secondary aim  
Mother-neonate pairs were included in the analyses if detailed neonatal anthropometric and cord 
blood metabolic data were available. Infants were included within the further analysis of data at 
6months of age if they attended that follow-up appointment and did not suffer from major ill 
health.  
Cord blood analyses  
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Cord blood biomarkers  
Candidate cord blood biomarkers assessed in this study include cord blood insulin, C-peptide, 
glucose, LDL-c, HDL-c, triglycerides, adiponectin, leptin, IGF I, II, IL-6 and TNF-α 
(Supplement Text 1). 
Metabolomic analyses 
A targeted cord plasma metabolome was analysed using mass spectroscopy, enabling the 
quantification of phospholipids, acylcarnitines, non-esterified fatty acids (NEFA), carboxylic 
acids and amino acids as described previously (Supplement Material Text 1) (9, 10). Analysis 
was undertaken in eight batches. 
Maternal variables  
Maternal clinical characteristics investigated, included maternal early pregnancy BMI (kg/m2); 
total GWG (kg) defined from pre-pregnancy to 34-36 weeks’ gestation; GDM defined using the 
IADPSG’s diagnostic criteria at 24-28+6 weeks’ gestation, and the fasting glucose, 1 and 2 hour 
glucose concentrations at the time of the OGTT (11).  
Offspring anthropometry  
Neonate  
Anthropometric measurements were made within 72 hours of birth by a trained midwife. 
Birthweight was recorded from maternal medical records and birthweight z-scores calculated 
using a UK reference population adjusted for sex and gestation at delivery (12). Neonatal 
subscapular and triceps skin fold thicknesses (SFT) were measured using Harpenden skinfold 
callipers in triplicate and the sum of skin fold thickesses (SSFT) were calculated. Neonatal 
length was assessed using a neonatometer. Abdominal and mid upper arm circumferences were 
assessed. 
Infant 
Anthropometric measurements were collected at 6 months of age by a trained midwife. Weight 
was assessed using SECA® scales, and length assessed in the supine position using an 
infantometer. Triceps and subscapular SFT were measured in triplicate using Holtain callipers. 
Where reference WHO population data were available, z-scores were calculated, adjusting for 
infant sex and age at measurement (13). Early catch-up growth was defined using the WHO 
definition of catch up growth, defined as an increase ≥0.67SDs in weight-z-scores from birth to 6 
months of age (13). Similarly catch down growth was defined as a decrease in weight-z-scores 
from birth to 6 months of age of ≥0.67SDs (13).  
Statistical analyses  
Cord blood metabolic profile  
To correct for potential batch effects with the cord blood metabolomics analysis, linear 
regression models were applied and the residuals were used for further statistical analysis. 
Metabolites were standardised to average metabolite concentrations and standard deviation over 
all eight batches for statistical analysis. Metabolites were included in the analyses if they had > 
70% complete data. Cord blood biomarkers and metabolomic variables were assessed for 
normality and transformed appropriately. Variables were summarised using mean (SD) and 
median (IQR) where appropriate.  
Principal component analysis was undertaken for the metabolomic data only, to reduce the 
number of metabolites based on a series of uncorrelated linear combinations of variables 
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containing the most variance. Following orthogonal rotation, metabolites with a loading ≥0.1 
were considered to have a strong association with the cluster.  
Effect of a lifestyle intervention on the cord blood metabolic profile  
Assessment was made for any differences in maternal characteristics and birth outcomes between 
those included vs. those excluded from the analysis. Adjustment was made for any apparent 
differences in maternal characteristics at trial entry (15+0-18+6 weeks’ gestation) between the two 
arms. The effect of the UPBEAT intervention was assessed using linear regression adjusting for 
minimisation variables used at trial randomisation (ethnicity, parity and maternal early 
pregnancy BMI). 
Maternal associations with cord blood metabolic profile  
Maternal antenatal variables (including early pregnancy BMI, GWG and GDM) were assessed in 
relation to the cord blood metabolic profile. To assess for potential relationships, multivariable 
linear regression was undertaken, where components of the cord blood metabolic profile were 
treated as the outcome and maternal antenatal variables as the exposure adjusting for offspring 
sex, gestational age at delivery and randomisation to the UPBEAT intervention.  
Cord blood metabolic profile and offspring anthropometry 
To assess the association between the cord blood metabolic profile (exposure) and subsequent 
offspring anthropometry (outcome) at birth and at 6 months, multivariable linear or logistic 
regression was undertaken where appropriate. 
Adjustment was made for confounders, selected a-priori based on clinical knowledge with 
the aid of directed acyclic graphs (DAGs) (Supplement Text 2). Unless a systematic approach is 
taken, adjusting for potential confounders may increase bias. The proper use of DAGs in 
selecting covariates is likely to reduce the degree of bias (14). Selected confounders included age 
at anthropometric measurement, offspring sex where appropriate and randomisation to the 
UPBEAT intervention (Model 1). Further adjustment was made for maternal parity, ethnicity 
(reference white ethnicity), current smoker in early pregnancy, GDM, GWG (Model 2).  For 
potential associations of metabolic profile at birth and infant anthropometry at 6 months of age, 
further adjustment was made for mode of feeding (reference exclusive breastfeeding ≥4 months 
of age).  
All linear regression models were further assessed for data points exhibiting high leverage by 
using Cook’s Distance (defined as Di>4/n), heteroscedasticity and linearity. Correction for 
multiple testing was undertaken using a false discovery rate utilising the Benjamin & Hochberg 
procedure. Presented significance levels were corrected for multiple testing (statistical 
significance p<0.05) (15).  
Sensitivity analyses 
Sensitivity analysis were undertaken by assessing demographic characteristics for those included 
within the analyses versus the mother-offspring pairs excluded. Sensitivity analyses were 
performed excluding offspring born <34 weeks’ gestation. A further sensitivity analyses was 
undertaken excluding mothers diagnosed with GDM. As mode of delivery has been shown to 
influence the cord blood metabolic profile, a fourth sensitivity analysis was undertaken with 
statistical models further adjusted for mode of delivery (reference category; unassisted vaginal 
delivery).  
All statistical analyses were performed using Stata Version 14.1.  
Results  
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Demography  
Of the 608 cord samples available from neonates born to women randomised to the UPBEAT 
trial, 343 mother-offspring pairs were included (Supplement Figure 2). Median maternal BMI 
was 35.6 kg/m2 (IQR 33.0, 38.9), 71.7% were of a white ethnic group and 87.8% were in the 
highest quintiles of socioeconomic deprivation. Median neonatal birthweight was 3.5 kg (IQR 
3.21, 3.82 kg) and 26.0% of offspring demonstrated significant catch-up growth as defined as 
>0.67 SD increase in infant weight z-scores between offspring birthweight and assessment at 6 
months of age. Further maternal, neonatal and infant demographics and anthropometric 
characteristics are provided in Table 1. To assess for potential selection bias, comparisons were 
made between mother-offspring pairs included and excluded from the analysis. The incidence of 
black ethnicity, neonatal birthweight and subscapular SFT were different between the two groups 
(Supplement Table 2). There was no difference in the incidence of GDM, total GWG or infant 
anthropometric measures between the two groups (Supplement Table 2).  
191 cord blood metabolites and 12 candidate biochemical markers were included in the 
analyses. Summary statistics of cord biochemical analyses including candidate biomarkers and 
metabolomic analyses are shown in Supplement Table 3. Following PCA, 4 distinct principal 
components of metabolites were identified which were; “Phosphatidylcholines”, “Non-esterified 
fatty acids”, “Long-chain Acylcarnitines and TCA metabolites” and “Amino acids” (Supplement 
Figure 3a-d).  
Effect of the UPBEAT intervention  
Mother’s included in this analysis were older, more likely to be nulliparous and less likely to be 
of black ethnic origin compared to those without a cord blood sample (Supplement Table 4). 
Following correction for multiple testing, there were no significant differences in the cord blood 
metabolic profile including clusters derived from PCA, between intervention and control arms 
(Supplement Figure 4).   
Relationships between maternal exposures and cord blood metabolic profile 
Diagnosis of maternal GDM was associated with reduced cord blood adiponectin and increased 
isocitric acid and lysophosphatidylcholine (LPC) 18.1 concentrations following correction for 
multiple testing by using a FDR (Supplement Figure 5). Both maternal early pregnancy BMI and 
total GWG were not associated with the cord blood metabolic profile (Supplement Figure 6 and 
7). Maternal fasting glucose collected at the time of the OGTT (28 weeks’ gestation) was 
positively associated with higher cord insulin, C-peptide, LPC 18.1, 18.2 and 20.4, alpha 
aminoadipic acid and citric acid following correction for multiple testing. Maternal fasting 
glucose was also associated with lower cord adiponectin and NEFA 26.0 (Figure 1). 
Associations between maternal glucose at 1 hour and 2 hour post OGTT are illustrated in 
Supplement Figure 8 and 9.  
Cord blood metabolic profile and neonatal anthropometry  
There was a positive linear relationship between cord C-peptide, insulin, IGF-1, leptin and 
neonatal birthweight z-scores, SSFT, subscapular SFT, triceps SFT (except for insulin, and C-
peptide), mid upper arm and abdominal circumference (Table 2, Supplement Figure 10). 
Principal components of NEFAs as assessed in the metabolome and cord blood triglycerides 
were inversely associated with neonatal birthweight z-scores, SSFT, subscapular SFT, triceps 
SFT and mid upper arm circumference at birth (Table 2, Supplement Figure 10). HDL, 
adiponectin and principal components of phosphatidylcholines were linearly associated with 
birthweight z-score only. LPC 16.1 and 18.0 were positively associated with neonatal birth 
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weight, SSFT, subscapular and triceps SFTs following correction for multiple testing (Figure 2). 
Cord blood cholesterol was not associated with any measure of neonatal anthropometry 
(Supplement Figure 10). Interleukin-6 and TNF-α were negatively associated with neonatal 
birthweight z-scores. There were no associations between cord principal components of 
acylcarnitines, amino acids and IGF-II with any measure of neonatal anthropometry (Table 2, 
Figure 2 and Supplement Figure 10). 
Cord blood metabolic profile and infant anthropometry at 6 months of age 
Of those biochemical variables, which were significantly associated with neonatal body 
composition, clusters of phosphatidylcholines and adiponectin were linearly associated with 
infant weight and length z-scores at 6 months of age (Figure 2, Supplement Table 5). In 
particular, LPC 16.1 and 18.1 were linearly associated with infant weight z-scores at 6 months of 
age (Figure 2, Supplement Table 5). Cord IGF-I was linearly associated with infant weight z-
scores, BMI z-score and mid upper arm circumference z-score (Figure 2, Supplement Table 5). 
Cord leptin and triglycerides were negatively associated with infant mid-upper arm 
circumference z-scores following adjustment for maternal and infant confounding (Figure 2, 
Supplement Table 5). There were no associations between cord insulin, glucose, C-peptide and 
IL-6 with infant anthropometry at 6 months of age (Figure 2, Supplement Table 5).  
For every unit increase in principal components of phosphatidylcholines, the odds of catch up 
growth at 6 months of age increased by 1.35 (1.04 to 1.75), whereas leptin decreased by 0.33 
(0.17 to 0.52) (Supplement Table 6). IGF-1 and leptin were positively associated with increased 
odds of catch down growth at 6 months of age (Supplement Table 6).   
Sensitivity analyses 
The associations between cord blood metabolic profile and neonatal or infant body composition 
remained unchanged following removal of offspring born <34 weeks’ gestation (N=36) 
(Supplement Figure 11 & 12), those participants exposed to GDM (n=111) (Supplement Figure 
13 & 14) and following further adjustment for mode of delivery (Supplement Figure 15 & 16).  
Discussion  
This study reports a comprehensive cord blood metabolic profile, including candidate 
biochemical markers and metabolome, in offspring born to obese mothers. By demonstrating 
associations with fasting glucose, it has been shown that in-utero exposure to maternal 
dysglycaemia in obese pregnancies has the potential to modify the cord blood metabolic profile 
at birth. Although there was no effect of the UPBEAT antenatal lifestyle intervention on the cord 
blood metabolic profile, when treating the data as a cohort, associations were observed between 
the cord blood metabolic profile and offspring growth in early life. The novel associations 
between cord lysophosphatidylcholines and neonatal adiposity, together with the relation with 
maternal hyperglycaemia may provide mechanistic insight into the early-life origins of obesity.   
The lack of effect of the UPBEAT intervention on the cord metabolic profile may suggest 
that the differences observed in the maternal secondary outcomes including reduction in 
adiposity and gestational weight gain were inadequate to have a major impact on fetal 
metabolism, although more subtle molecular effects could have occurred to influence adiposity 
in the six month infants as recently reported (8). Principal components of phosphatidylcholines 
and lysophosphatidylcholines were found to be positively associated with early growth velocities 
and weight z-scores, providing possible mechanistic insight of the mechanisms contributing to 
early postnatal growth in offspring born to obese women. The finding that principal components 
  8
of cord lysophosphatidylcholines, primarily lysophosphatidylcholines 16.1 and 
lysophosphatidylcholines 18.1 were not only associated with neonatal weight-z-scores, but also 
infant growth and catch-up growth within the first 6 months of age provides novel evidence, 
suggesting a role in the early life growth velocities. Of relevance, associations with cord 
lysophosphatidylcholines and birthweight were recently reported in a birth cohort from Germany 
(6). In the present study lysophosphatidylcholines were associated with neonatal adiposity as 
well as birthweight; supporting a role in body fat accretion. It may be of relevance to these 
observations that the infant growth trajectory in the first 6 months of life has been shown to be 
predictive of adolescence and early adulthood obesity (16) and that The European Childhood 
Obesity Programme has shown that lysophosphatidylcholines 14.0 correlate with rapid growth in 
infancy and subsequent obesity at 6 years of age (17). Together these findings would suggest a 
possible role for lysophosphatidylcholines in the early life ‘programming’ of obesity risk (18).  
Further interrogation of the dataset demonstrated a significant linear relationship between 
cord blood insulin, C-peptide and IGF-1 with cord lysophosphatidylcholines (Supplement Figure 
17 &18) supporting the suggestion of an interaction between fetal glucose homeostasis and these 
molecules(19). This observation is in part supported by one small case-control study (n=46) that 
identified an inverse relationship between maternal gestational diabetes and placental uptake of 
lysophosphatidylcholines 22:6, in women of heterogeneous BMI (20). A role in fetal metabolism 
for lysophosphatidylcholines has also been suggested in the non-pregnant state with the 
development of visceral fat obesity, unrelated to genetic origin but associated with nutritional 
status (21). A study from the USA Project Viva cohort, demonstrated that associations between 
cord blood metabolites from a  metabolome, particularly those related to one-carbon metabolism 
may contribute to rapid postnatal weight gain in offspring born to women of heterogeneous BMI 
(22). Taken together, studies of the cord blood metabolic profile suggest that obesity risk may be 
determined at birth (4). Antenatal interventions directed towards optimising adverse fetal 
exposures may therefore contribute to curbing the incidence of childhood obesity.  
The positive associations between cord blood IGF-1 with neonatal measures of growth and 
body composition together with infant weight and mid upper arm circumference z-scores at 6 
months also suggests a persistent influence of in-utero exposures on early growth. Whilst the 
relationship between the cord blood metabolic profile and differential growth in early infancy 
suggests a potential persistent effect on growth at 6 months of age, mechanisms must remain 
conjectural and causal inference should be made with caution.  However, several studies have 
suggested that the IGF-1 gene may be prone to epigenetic modification in-utero (23-25), with 
animal studies shedding some light on this in providing evidence of an interaction with maternal 
glycaemia status. For example, Zinkhan et al, demonstrated that in-utero exposure to maternal 
glycaemia in rats led to decreased hepatic H3Me3K36 and mRNA variants of the IGF-1 gene in 
the offspring (26). Others have implicated a role of these variants to a predisposition to later 
obesity and insulin resistance (25). Whether epigenetic modification may also influence lipid 
metabolism, including that of lysophosphatidylcholines, remains conjectural.  
The linear associations with cord adiponectin and measures of weight, length and 
subscapular z-scores at 6 months are in keeping with recent evidence from a prospective cohort 
study from Germany, in children born to women of heterogeneous BMI (n=141); suggesting a 
potential long term influence in children at 5 years of age (27). We also found that cord blood 
leptin was associated with measures of neonatal growth and body composition and increased 
odds of catch up growth from birth to 6 months of age, suggesting a potential mediatory role of 
early infancy growth. Cord blood leptin has been implicated as a proxy for neonatal fat mass as it 
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is synthesised by the adipocyte Ob gene and is proportional to adipose tissue mass (28). This 
study has demonstrated an inverse relationship with cord leptin and catch up growth independent 
of birthweight which may be explainable by a state of leptin resistance in early infancy, as 
observed in previous studies (29). 
The linear associations between cord blood anabolic hormones including cord blood C-
peptide, insulin and IGF-1 with measures of growth and body composition at birth, agree with 
previous studies in offspring born to women of heterogeneous BMI (30, 31) and concur with the 
knowledge that insulin and IGF-1 are the most important regulators of fetal growth in the 2nd and 
3rd trimester (32). IGF-1 has been shown consistently to be raised in cord blood of offspring born 
to obese women, predominately as a consequence of maternal dysglycaemia (33).  
Triglycerides and non-esterified fatty acids in the maternal circulation have been widely 
implicated as determinants of fetal growth in obese and diabetic women (32). However, in this 
study, an inverse relationship between clusters of non-esterified fatty acids and triglycerides with 
neonatal growth and adiposity was observed, which has also been reported by others(34, 35). 
This association with low rather than high birth weight could reflect mobilisation of lipids as an 
alternative fuel source (34). Importantly, this study adds to others that have questioned the role 
of triglycerides in the determination of neonatal adiposity.  
Despite the suggestion that inflammatory mediators (interleukin-6 and tumour necrosis 
factor-α) may contribute to the development of neonatal adiposity in-utero, through regulation of 
central pathways of satiety and appetite, (36, 37). We found an inverse association with neonatal 
body composition. There is no obvious explanation for this observation. 
Strengths of this study include an extensive assessment of the cord blood metabolic profile at 
birth, detailed neonatal and infant anthropometric data collection and prospective collection of 
maternal early pregnancy BMI, total gestational weight gain and measures of maternal insulin 
resistance. Using data reduction techniques for the cord blood metabolome, metabolite clusters 
of biological importance associated with measures of neonatal and infant anthropometry were 
identified.  
Limitations include the collection of mixed cord blood (umbilical artery and vein), which 
weakens conclusions regarding fetal or maternal origin of the metabolites in this study, as well as 
previously published reports (22). Whilst treatment of GDM has the potential to influence cord 
insulin, C-peptide and IGF-1 concentrations, this was not adjusted for within this analysis, 
however a sensitivity analyses removing women with GDM did not modify the observed 
relationships. It must be recognised that the metabolome and the candidate markers measured 
provide only an incomplete profile of the late pregnancy in-utero fetal exposures as unmeasured 
micronutrients, essential fatty acids and steroid hormones may also contribute to neonatal and 
early life growth and body composition.  
In summary, this study of more than 300 infants describes for the first time a comprehensive 
cord blood metabolic profile in offspring born to obese women. Known associations of metabolic 
variables with infant adiposity were confirmed and questions raised regarding previous 
associations derived from smaller cohorts. Importantly we have highlighted novel associations 
with lipid sub-species and early postnatal growth, and provide supporting evidence that IGF-1 at 
birth may be a determinant of later growth trajectories. Current investigation of the maternal 
metabolome and neonatal epigenome may shed light on the causative mechanisms and further 
insight into growth trajectories. Ongoing studies of the cord epigenome may provide further 
mechanistic insight into potential pathways. Replication in other cohorts including the use of 
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Mendelian randomisation methods are required to determine causality. Ongoing follow-up of the 
UPBEAT offspring will address the long-term implications of these observed associations.  
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Figure 1: Volcano plot demonstrating the association of maternal fasting glucose at the 
time of the oral glucose tolerance test with the cord blood metabolic profile from infants 
born to obese pregnant women (n=607). Parameter estimates are graphically represented for 
each biochemical variable in relation to maternal clinical characteristics following adjustment 
using a false discovery rate (Benjamin & Hochberg procedure) (17). Statistical significance 
p<0.0027. Abbreviations; CARN-Carnitines;  HDL-High density lipoprotein; IGFI- Insulin 
growth factor I; IGF II- Insulin growth factor II; IL6- Interleukin 6; LPC- 
lysophosphatidylcholines; LPCE- lysophosphatidylethanolamine; PC-phosphatidylcholines; 
PCA- diacylphosphatidylcholines; PCE- acylalkylphosphatidylcholines; SM- sphingomyelins. 
TNFalpha- Tumor necrosis factor; X30B- x3methyl2oxobutanoicacid; X30V-- 
x4methyl2oxovalvericacid. NEFAs are described using the nomenclature CX:Y, where X is the 
length of the carbon chain, Y is the number of double bonds, OH in the formula means the 
molecule contains a hydroxyl-group. 
Figure 2: Heat map demonstrating associations between cord blood metabolites with 
anthropometric measurements in neonates (n=344) and six month old infants (n=209). Data 
from infants born to obese pregnant women in the UPBEAT study. Regression coefficients 
plots with adjustment made for maternal parity, ethnicity, smoker in early pregnancy, gestational 
diabetes, gestational weight gain, offspring sex, gestation at delivery, randomisation to UPBEAT 
Intervention. Additional adjustment is made for early mode of infant feeding for infant 
anthropometry data at 6 months of age. Abbreviations; BW- Neonatal birthweight z-scores 
(SDs); CARN-Carnitines; LPC- lysophosphatidylcholines; LPCE- 
lysophosphatidylethanolamine; MUAC- Mid upper arm circumference (cm); PC-
phosphatidylcholines; PCaa- diacylphosphatidylcholines; PCae- acylalkylphosphatidylcholines 
SM- sphingomyelins; SSF- Sum of skinfold thicknesses (mm); Tri SFT- Triceps skinfold thickness 
(mm); Sub SFT- Subscapular skinfold thickness (mm). NEFAs are described using the 
nomenclature CX:Y, where X is the length of the carbon chain, Y is the number of double bonds, 
OH in the formula means the molecule contains a hydroxyl-group.  
Table  1: Maternal, neonatal and infant demographic, anthropometry and clinical characteristics 
of mother-offspring pairs by randomisation allocation (n=343). 
 Intervention  Control  All   
N Mean (SD)/ 
Median 
(IQR)/ N(%) 
N Mean (SD)/ 
Median (IQR)/ 
N(%) 
N Mean (SD)/ 
Median (IQR)/ 
N(%) 
Maternal      
Age (years) 169 31.0 (28.0, 
35.0) 
174 31.0 (27.0, 
35.0) 
343 31.0 (27.0, 35.0) 
BMI (kg/m2) 169 35.5 (33.0, 
39.1) 
174 35.7 (33.0, 
38.5) 
343 35.6 (33.0, 38.9) 
Ethnicity 
Asian  
169 
12 (7.1) 
174 
7 (4.0) 343 19 (5.5) 
Black  32 (18.9) 31 (17.8)  63 (18.4) 
Other  7 (4.1) 8 (4.6)  15 (4.4) 
White  118 (69.8) 128 (73.6)  246 (71.7) 
Multiparous 169 86 (50.9) 174  79 (45.4) 343 165 (48.1) 
Smoker in early pregnancy 169 7 (4.1) 174 12 (6.9) 343 19 (5.5) 
Socioeconomic deprivation  169 145 (85.7) 174 151 (86.8) 343 295 (87.8) 
Gestational weight gain (kg) 169 6.94 (4.27) 174 8.00 (3.79) 343 7.78 (4.07) 
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Gestational diabetes  169 59 (34.9) 174 52 (29.9) 343 111 (32.4) 
Neonate     
Mode of delivery 
Vaginal 
169 
73 (43.2) 
174 
65 (37.4) 343 138 (40.2) 
Operative 
vaginal  
25 (14.8) 19 (10.9)  44 (12.8) 
Emergency C-
section   
28 (16.6) 50 (28.7)  78 (22.7) 
Elective C-
section 
43 (25.4) 40 (23.0)  83 (24.2) 
Gestation at delivery (weeks) 169 39.7 (38.7, 
40.7) 
174 40.0 (38.7, 
41.0) 
343 39.9 (38.7, 40.9) 
Birthweight (kg) 169 3.51 (3.22, 
3.79) 
174  3.59 (3.19, 
3.86) 
343  3.6 (3.2, 3.8) 
Birthweight z scores  169  0.12 (0.99) 174 0.13 (0.99) 343 0.21 (0.76) 
Skinfold thickness-subscapular (mm) 169 5.81 (1.46) 174 5.75 (1.37) 343 5.78 (1.42) 
Skinfold thickness triceps (mm) 169 5.33 (1.42) 174 5.34 (1.49) 343 5.34 (1.45) 
Sum of skinfold thicknesses (mm) 169 11.14 (2.61) 174 11.09 (2.58) 343 11.12 (2.59) 
Midarm circumference (cm)  169 11.57 (0.98) 174 11.59 (0.97) 343 11.58 (0.97) 
Abdominal circumference (cm) 169 32.71 (2.11) 174 32.57 (1.99) 343 32.63 (2.05) 
Infant      
Weight for age z-score  125 0.17 (1.04) 123 0.42 (0.97) 247 0.29 (1.01) 
Length for age z-score 120  0.36 (1.71) 119 0.54 (1.99) 238 0.44 (1.85) 
BMI for age z-score  120 -0.00 (1.62) 119 0.21 (2.02) 238 0.10 (1.84) 
Arm circumference z-score  125 1.11 (0.92) 122 1.40 (1.86) 246 1.25 (1.47) 
Triceps skinfold thickness z-score 124 0.17 (1.59) 119  0.44 (1.42) 242 0.29 (1.51) 
Subscapular skinfold thickness  z-
score 
107 0.23 (1.42) 103 0.37 (1.49) 209 0.30 (1.45) 
Catch up growth*  125 31 (24.8) 122 34 (27.9) 246 64 (26.0) 
Catch down growth**  125 36 (28.8) 122 24 (19.7) 246 60 (24.4) 
Abbreviations BMI-Body Mass Index. *Catch up growth defined as a ≥ 0.67 SDs increase in weight-z-scores from 
birth to 6 months of age. **Catch down growth defined as a ≥0.67 SDS decrease in weight-z-scores from birth to 6 
months of age. 
Table 2: Associations of the cord blood metabolic profile with neonatal anthropomety in infants 
born to obese pregnant women (n=344) 
 Birthweight z-
scores (SDS)  
SSFT (mm) Subscapular 
SFT (mm) 
Triceps SFT 
(mm) 
MUAC (cm) Abdominal 
circumference 
(cm) 
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) 
PCA-
Phosphatidylcholin
es 
0.04 (0.02 to 
0.07)** 
-0.11 (-0.25 to 
0.03) 
-0.06 (-0.12 to 
0.01) 
-0.05 (-0.15 to 
0.04) 
0.03 (-0.02 to 
0.07) 
0.01 (-0.10 to 
0.11) 
PCA- NEFA -0.04 (-0.08 to 
0.00)* 
-0.28 (-0.49 to -
0.08)* 
-0.11 (-0.21 to 
0.00)* 
-0.18 (-0.32 to -
0.03)* 
0.02 (-0.05 to 
0.10) 
-0.01 (-0.17 to 
0.15) 
PCA- Long chain 
acylcatnitines and 
TCA metabolites 
0.00 (-0.04 to 
0.04) 
-0.05 (-0.27 to 
0.17) 
-0.02 (-0.13 to 
0.09) 
-0.03 (-0.18 to 
0.12) 
-0.01 (-0.08 to 
0.07) 
0.01 (-0.15 to 
0.17) 
PCA-Amino acids  0.05 (0.00 to 
0.11) 
-0.05 (-0.36 to 
0.25) 
0.06 (-0.09 to 
0.20) 
-0.11 (-0.32 to 
0.10) 
0.06 (-0.04 to 
0.16) 
0.19 (-0.03 to 
0.40) 
Cpeptide (log2) 
ng/ml 
0.27 (0.14 to 
0.39)** 
0.86 (0.22 to 
1.50)* 
0.52 (0.17 to 
0.87)* 
0.34 (-0.02 to 
0.69) 
0.25 (0.00 to 
0.49)* 
0.73 (0.22 to 
1.25)* 
Insulin (log2) U/ml 0.16 (0.09 to 
0.23)** 
0.47 (0.12 to 
0.82)* 
0.31 (0.11 to 
0.50)* 
0.17 (-0.03 to 
0.37) 
0.16 (0.02 to 
0.29)* 
0.38 (0.10 to 
0.67)* 
Glucose (log2) 
mmol/l 
-1.80 (-3.59 to 
0.00)* 
-2.94 (-12.96 to 
7.08) 
-3.68 (-9.32 to 
1.96) 
0.48 (-4.94 to 
5.90) 
-2.13 (-6.01 to 
1.75) 
-6.19 (-14.48 to 
2.09) 
Triglycerides 
mmol/l 
-0.47 (-0.74 to -
0.20)** 
-1.65 (-3.18 to -
0.11)* 
-0.95 (-1.82 to -
0.08)* 
-0.73 (-1.56 to 
0.10) 
-0.90 (-1.48 to -
0.33)* 
-1.05 (-2.32 to 
0.22) 
Cholesterol mmol/l 0.13 (-0.06 to 
0.32) 
-0.75 (-1.68 to 
0.17) 
-0.45 (-0.97 to 
0.07) 
-0.31 (-0.81 to 
0.19) 
-0.11 (-0.48 to 
0.25) 
0.40 (-0.38 to 
1.17) 
HDL mmol/l 0.22 (0.06 to 
0.38)* 
-0.11 (-0.89 to 
0.67) 
-0.25 (-0.68 to 
0.17) 
0.16 (-0.28 to 
0.60) 
0.02 (-0.27 to 
0.32) 
0.38 (-0.25 to 
1.01) 
IGFI (log2) ng/ml 1.13 (0.97 to 
1.29)** 
1.80 (0.89 to 
2.72)** 
1.08 (0.58 to 
1.59)** 
0.72 (0.20 to 
1.24)* 
1.19 (0.87 to 
1.51)** 
2.41 (1.70 to 
3.12)** 
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IGFII (log2) ng/ml 0.31 (-0.02 to 
0.65) 
1.57 (-0.15 to 
3.29) 
0.68 (-0.27 to 
1.63) 
0.89 (-0.08 to 
1.85) 
0.29 (-0.37 to 
0.96) 
0.54 (-0.86 to 
1.93) 
Leptin (log2) ng/ml 0.38 (0.30 to 
0.46)** 
1.59 (1.21 to 
1.97)** 
0.83 (0.62 to 
1.04)** 
0.76 (0.54 to 
0.98)** 
0.50 (0.35 to 
0.66)** 
0.80 (0.47 to 
1.13)** 
Adiponectin (log2) 
ug/ml 
0.40 (0.12 to 
0.68) 
0.64 (-0.79 to 
2.08) 
0.48 (-0.31 to 
1.27) 
0.07 (-0.73 to 
0.87) 
0.84 (0.31 to 
1.37)* 
1.16 (0.00 to 
2.31)* 
IL6 (log2) pg/ml -0.04 (-0.07 to 
0.00)* 
0.06 (-0.11 to 
0.23) 
-0.02 (-0.11 to 
0.08) 
0.08 (-0.02 to 
0.17) 
-0.04 (-0.11 to 
0.03) 
-0.14 (-0.28 to 
0.00)* 
TNF alpha (log2) 
pg/ml 
-0.58 (-1.12 to -
0.03)* 
-1.44 (-4.21 to 
1.32) 
-0.72 (-2.25 to 
0.80) 
-0.86 (-2.41 to 
0.69) 
-0.84 (-1.87 to 
0.19) 
-0.61 (-2.82 to 
1.60) 
Regression coefficients with corresponding 95% confidence intervals presented are adjusted for maternal parity, 
ethnicity, smoker in early pregnancy, gestational diabetes, gestational weight gain, offspring sex, gestation at 
delivery, randomisation to UPBEAT Intervention. Abbreviations; HDL- High density lipoprotein; IGFI- Insulin 
growth factor I; IGFII- Insulin growth factor II; IL6-Interleukin 6; MUAC-Mid upper arm circumference; NEFA- 
Non-esterified fatty acids;  SDS- Standard deviation scores; SFT- skinfold thickness; TCA- Tricarboxylic acid; 
TNFalpha- Tumour Necrosis Factor alpha.  *p<0.05; ** p<0.001.  


